Meningococcal polysaccharide vaccine group W-135

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Meningococcal polysaccharide vaccine group W-135
Accession Number
DB13887
Description

Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Meningococcal polysaccharide antigen group W-135
  • neisseria meningitidis group W-135 capsular polysaccharide antigen
  • Neisseria meningitidis group W-135 polysaccharide antigen, A

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)SubcutaneousSanofi Pasteur Inc.1981-11-232017-09-10US flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (50 mcg) + Meningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Meningococcal polysaccharide vaccine group Y (50 mcg)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (500 mcg) + Meningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Meningococcal polysaccharide vaccine group Y (500 mcg)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (2.5 mg) + Meningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Meningococcal polysaccharide vaccine group Y (2.5 mg)Powder, for solutionSubcutaneousAventis Pasteur Limited1998-08-132006-07-17Canada flag
MenveoMeningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada flag
NimenrixMeningococcal polysaccharide vaccine group W-135 (5 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (44 mcg) + Meningococcal polysaccharide vaccine group A (5 mcg) + Meningococcal polysaccharide vaccine group C (5 mcg) + Meningococcal polysaccharide vaccine group Y (5 mcg)Kit; Powder, for solutionIntramuscularPfizer Canada Ulc2013-08-22Not applicableCanada flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
9F8QQ6EER1
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911456
RxNav
314724
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionMeningococcal Disease, Invasive1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceBloodstream Infections / Meningitis / Meningococcal Disease1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Meningitis / Meningococcal sepsis / Pertussis / Tetanus1
4CompletedPreventionMeningitis / Meningococcal Disease1
4CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis2
4CompletedPreventionMeningococcal Disease1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4CompletedTreatmentMeningitis / Meningococcal Infections / Meningococcal Meningitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular4 mcg/500mcL
Injection, solutionIntramuscular4 mcg/0.5ml
SolutionIntramuscular4 mcg
Injection, powder, for suspension50 mcg
Injection, powder, for solutionSubcutaneous50 mcg/0.5ml
Kit; powder, for solutionSubcutaneous
Powder, for solutionSubcutaneous
Injection, powder, for solutionIntramuscular10 mcg/0.5mL
PowderIntramuscular10 mcg
Powder, for solution; solutionIntramuscular
Injection, powder, lyophilized, for solutionIntramuscular10 mcg/0.5ml
Injection, powder, for solutionIntramuscular5 mcg
Kit; powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular5 mcg/0.5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 08, 2017 14:22 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates